{"disease":{"id":"diabetes-mellitus-type-2","name":"Diabetes mellitus type 2","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":62,"pipeline_drug_count":0,"trial_count":6},"drugs":{"marketed":[{"drug_id":"semaglutide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ozempic","generic_name":"semaglutide","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":90,"revenue":"27400","mechanism":"Semaglutide, a GLP-1 analogue, lowers blood glucose by stimulating insulin and inhibiting glucagon secretion in a glucose-dependent manner, and delays gastric emptying."},{"drug_id":"tirzepatide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mounjaro","generic_name":"TIRZEPATIDE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"GIP receptor and GLP-1 receptor","drug_class":"Dual GIP/GLP-1 receptor agonist","quality_score":84,"revenue":"15530","mechanism":"Tirzepatide is a dual GIP and GLP-1 receptor agonist with C20 fatty diacid for albumin binding."},{"drug_id":"dulaglutide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trulicity","generic_name":"DULAGLUTIDE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":63,"revenue":"7200","mechanism":"Dulaglutide activates GLP-1 receptors, increasing insulin release and decreasing glucagon secretion and gastric emptying."},{"drug_id":"empagliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jardiance","generic_name":"empagliflozin","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":66,"revenue":"6500","mechanism":"SYNJARDY combines empagliflozin, which inhibits SGLT2 to increase urinary glucose excretion, and metformin HCl, which improves glucose tolerance and insulin sensitivity."},{"drug_id":"dapagliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Farxiga","generic_name":"DAPAGLIFLOZIN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":69,"revenue":"6300","mechanism":"Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine."},{"drug_id":"insulin-glargine","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lantus","generic_name":"INSULIN GLARGINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":70,"revenue":"4800","mechanism":"Lantus works by mimicking the action of natural insulin to lower blood sugar levels."},{"drug_id":"sitagliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Januvia","generic_name":"SITAGLIPTIN","company_name":"Zydus Lifesciences","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":75,"revenue":"3200","mechanism":"Januvia works by blocking an enzyme that breaks down hormones that help the body release insulin."},{"drug_id":"liraglutide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Victoza","generic_name":"liraglutide","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":35,"revenue":"3200","mechanism":null},{"drug_id":"insulin-lispro","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humalog","generic_name":"INSULIN LISPRO","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":70,"revenue":"2200","mechanism":"Humalog works by mimicking the natural hormone insulin to help cells absorb glucose from the bloodstream."},{"drug_id":"canagliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invokana","generic_name":"CANAGLIFLOZIN","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":71,"revenue":"800","mechanism":"Invokana works by blocking the SGLT2 protein in the kidneys to reduce glucose reabsorption."},{"drug_id":"bi-1356","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tradjenta","generic_name":"BI 1356","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":71,"revenue":"800","mechanism":"Tradjenta works by blocking the DPP-4 enzyme, which normally breaks down incretin hormones that help regulate blood sugar levels."},{"drug_id":"linagliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tradjenta","generic_name":"LINAGLIPTIN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":75,"revenue":"800","mechanism":"Tradjenta works by blocking an enzyme that breaks down hormones that help the body release insulin."},{"drug_id":"vildagliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jalra","generic_name":"VILDAGLIPTIN","company_name":"","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"vildagliptin","quality_score":37,"revenue":"159","mechanism":""},{"drug_id":"acetohexamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dymelor","generic_name":"ACETOHEXAMIDE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"acetohexamide","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"bexagliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brenzavvy","generic_name":"BEXAGLIFLOZIN","company_name":"Theracosbio","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":58,"revenue":null,"mechanism":"Bexagliflozin inhibits SGLT2 to reduce renal glucose reabsorption and increase urinary glucose excretion."},{"drug_id":"metformin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucophage","generic_name":"metformin","company_name":"Generic (originally Merck Serono/Lipha)","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Activates AMP-activated protein kinase (AMPK) to reduce hepatic glucose production and improve insulin sensitivity without causing hypoglycemia."},{"drug_id":"ertugliflozin-15-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 15 mg","generic_name":"ertugliflozin-15-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"januvia","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Januvia","company_name":"Johns Hopkins University","drug_phase":"discontinued","molecular_target":"Dipeptidyl peptidase 2, Dipeptidyl peptidase 8, Dipeptidyl peptidase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"duvie","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"duvie","company_name":"Pusan National University Hospital","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"liraglutid","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Liraglutid","company_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"pioglitazone","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Actos","generic_name":"pioglitazone","company_name":"Takeda","drug_phase":"marketed","molecular_target":"CDGSH iron-sulfur domain-containing protein 2, Bile salt export pump, CDGSH iron-sulfur domain-containing protein 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"saxenda","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Saxenda","company_name":"Seoul National University Hospital","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"victoza","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Victoza","company_name":"Hanmi Pharmaceutical Company Limited","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"glucophage","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glucophage","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"glipizide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucotrol","generic_name":"GLIPIZIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea [EPC]","quality_score":62,"revenue":null,"mechanism":"Glucotrol works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells."},{"drug_id":"lantus","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lantus","company_name":"Rijnstate Hospital","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"mitiglinide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MITIGLINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"mitiglinide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tofogliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Apleway","generic_name":"TOFOGLIFLOZIN","company_name":"","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"gliclazide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diabyl","generic_name":"GLICLAZIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"gliclazide","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"lobeglitazone","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duvie","generic_name":"LOBEGLITAZONE","company_name":"Chong Kun Dang","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor gamma","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"lyumjev","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lyumjev","company_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"dapa","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAPA","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"nateglinide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Starlix","generic_name":"NATEGLINIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Glinide [EPC]","quality_score":75,"revenue":null,"mechanism":"Starlix works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells."},{"drug_id":"glymidine","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gondafon","generic_name":"GLYMIDINE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"glymidine","quality_score":null,"revenue":null,"mechanism":"Gondafon works by stimulating insulin release from the pancreas."},{"drug_id":"voglibose","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glustat","generic_name":"VOGLIBOSE","company_name":"","drug_phase":"marketed","molecular_target":"Lysosomal alpha-glucosidase","drug_class":"voglibose","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"alogliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nesina","generic_name":"ALOGLIPTIN","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"Dipeptidyl Peptidase 4 Inhibitor","quality_score":65,"revenue":null,"mechanism":"Nesina works by blocking an enzyme that breaks down incretin hormones, allowing more insulin to be released and less glucagon."},{"drug_id":"insulin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humulin","generic_name":"insulin","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Lck","drug_class":"Insulin Analog [EPC]","quality_score":60,"revenue":null,"mechanism":"Humulin works by binding to insulin receptors on cells, triggering a cascade of signals that lower blood glucose levels."},{"drug_id":"ertugliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Steglatro","generic_name":"ERTUGLIFLOZIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter","drug_class":"","quality_score":54,"revenue":null,"mechanism":"Steglatro works by blocking the kidneys' ability to reabsorb glucose, allowing excess glucose to be excreted in the urine."},{"drug_id":"lixisenatide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adlyxin","generic_name":"LIXISENATIDE","company_name":"Sanofi-Aventis Us Llc","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"Insulin Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Adlyxin works by mimicking the action of the GLP-1 hormone to help regulate blood sugar levels."},{"drug_id":"ertugliflozin-5-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 5 mg","generic_name":"ertugliflozin-5-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"sotagliflozin","indication_name":"Diabetes mellitus type 2 at increased risk of cardiovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inpefa","generic_name":"SOTAGLIFLOZIN","company_name":"Lexicon Pharms Inc","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels."},{"drug_id":"buformin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butformin","generic_name":"BUFORMIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"buformin","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"troglitazone","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezulin","generic_name":"TROGLITAZONE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Forkhead box protein M1","drug_class":"troglitazone","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tolbutamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aglicid","generic_name":"TOLBUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"albiglutide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Albugon","generic_name":"ALBIGLUTIDE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"GLP-1 Receptor Agonist","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"miglitol","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glyset","generic_name":"MIGLITOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Lysosomal alpha-glucosidase","drug_class":"alpha-Glucosidase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Glyset works by delaying the breakdown of carbohydrates in the gut, allowing less glucose to enter the bloodstream."},{"drug_id":"forxiga","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Forxiga","company_name":"AstraZeneca Turkey","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"jardiance","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Jardiance","company_name":"University of Louisville","drug_phase":"marketed","molecular_target":"Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1, Sodium/glucose cotransporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"farxiga","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Farxiga","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"rybelsus","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rybelsus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"humalog","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humalog","company_name":"Halozyme Therapeutics","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gemigliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zemiglo","generic_name":"GEMIGLIPTIN","company_name":"","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"gemigliptin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mounjaro","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mounjaro","company_name":"Nicholas Skertich","drug_phase":"marketed","molecular_target":"Gastric inhibitory polypeptide receptor, Glucagon-like peptide 1 receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"anagliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suiny","generic_name":"ANAGLIPTIN","company_name":"","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"ipragliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suglat","generic_name":"IPRAGLIFLOZIN","company_name":"","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"glisoxepide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glisepin","generic_name":"GLISOXEPIDE","company_name":"","drug_phase":"phase_2","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"glisoxepide","quality_score":28,"revenue":null,"mechanism":"Glisoxepide works by blocking potassium channels in the pancreas, allowing more insulin to be released."},{"drug_id":"dapaglifozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dapaglifozin","company_name":"MedImmune LLC","drug_phase":"phase_3","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"evogliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suganon","generic_name":"EVOGLIPTIN","company_name":"Dong-A ST","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"glibenclamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micronase","generic_name":"glibenclamide","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"imeglimin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Twymeeg","generic_name":"IMEGLIMIN","company_name":"SUMITOMO DAINIPPON PHARMA Co., Ltd.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"tradjenta","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tradjenta","company_name":"EMS","drug_phase":"discontinued","molecular_target":"Dipeptidyl peptidase 9, Prolyl endopeptidase FAP, Dipeptidyl peptidase 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"glimepiride","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amaryl","generic_name":"GLIMEPIRIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea [EPC]","quality_score":62,"revenue":null,"mechanism":"Amaryl works by binding to the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel, closing the channel and depolarizing the pancreatic beta cell membrane, leading to insulin release."},{"drug_id":"acarbose","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Precose","generic_name":"ACARBOSE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Sucrase-isomaltase, intestinal","drug_class":"alpha-Glucosidase Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"chlorpropamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diabinese","generic_name":"CHLORPROPAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"carbutamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Burcol","generic_name":"CARBUTAMIDE","company_name":"","drug_phase":"phase_2","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"carbutamide","quality_score":null,"revenue":null,"mechanism":"Burcol works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells."}],"pipeline":[],"offLabel":[],"totalMarketed":65,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02958995","title":"Epidemiologic Study Of Diabetes And Cancer Risk","phase":"","overall_status":"COMPLETED","enrollment_count":2738161,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04017221","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":1249636,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT03492580","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":714582,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04572165","title":"Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data","phase":"","overall_status":"UNKNOWN","enrollment_count":600000,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05161429","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","phase":"","overall_status":"UNKNOWN","enrollment_count":550000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05882071","title":"Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":547150,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05730582","title":"Increasing Uptake of EHR-enabled Population Health Outreach Strategies to Improve Diabetes Screening","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500000,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT05162014","title":"To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin","phase":"","overall_status":"COMPLETED","enrollment_count":494679,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03464045","title":"Empa PASS on Urinary Tract Malignancies","phase":"","overall_status":"COMPLETED","enrollment_count":344995,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT02864914","title":"Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors","phase":"","overall_status":"COMPLETED","enrollment_count":333580,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03817463","title":"A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":327624,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06330480","title":"Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":320000,"lead_sponsor_name":"Prof. Dr. Folkert W. Asselbergs","has_results":false},{"nct_id":"NCT02958956","title":"Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.","phase":"","overall_status":"COMPLETED","enrollment_count":236507,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03363464","title":"Comparative Effectiveness of Empagliflozin in the US","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230000,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT07513259","title":"Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":203424,"lead_sponsor_name":"Chung Shan Medical University","has_results":false},{"nct_id":"NCT02636192","title":"Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02197078","title":"Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin","phase":"","overall_status":"COMPLETED","enrollment_count":189426,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03092752","title":"Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV","phase":"","overall_status":"COMPLETED","enrollment_count":162116,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06659744","title":"Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims","phase":"","overall_status":"COMPLETED","enrollment_count":158310,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT02857764","title":"Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":127690,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06251323","title":"Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)","phase":"NA","overall_status":"RECRUITING","enrollment_count":119680,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT02993614","title":"Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors","phase":"","overall_status":"COMPLETED","enrollment_count":99999,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05465317","title":"Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease","phase":"","overall_status":"COMPLETED","enrollment_count":62197,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06914102","title":"Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":58387,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT00659282","title":"Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":57610,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03534921","title":"Improving Diabetes Outcomes for People With Severe Mental Illness (SMI)","phase":"","overall_status":"COMPLETED","enrollment_count":46564,"lead_sponsor_name":"University of York","has_results":false},{"nct_id":"NCT06659718","title":"Emulation of the SOUL Diabetes Trial in Healthcare Claims","phase":"","overall_status":"COMPLETED","enrollment_count":43650,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06351748","title":"Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)","phase":"","overall_status":"COMPLETED","enrollment_count":34238,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT01696266","title":"An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":29304,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06914141","title":"Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction","phase":"","overall_status":"COMPLETED","enrollment_count":28118,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03993132","title":"A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":26774,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06659679","title":"Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims","phase":"","overall_status":"COMPLETED","enrollment_count":26126,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04928248","title":"Design, Implementation and Evaluation of Scalable Decision Support for Diabetes Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":25915,"lead_sponsor_name":"University of Utah","has_results":false},{"nct_id":"NCT03249506","title":"Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)","phase":"","overall_status":"COMPLETED","enrollment_count":25358,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04295005","title":"A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists","phase":"","overall_status":"COMPLETED","enrollment_count":24500,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03627039","title":"Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05874635","title":"Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Signos Inc","has_results":false},{"nct_id":"NCT04034524","title":"Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05441267","title":"A Study of Cardiovascular Events iN Diabetes Plus","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT01991795","title":"A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":19271,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06573905","title":"Mapping Diabetes in Quebec: Validating Medico-administrative Algorithms for Type 1 Diabetes, Type 2 Diabetes and LADA","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":17271,"lead_sponsor_name":"Universite du Quebec en Outaouais","has_results":false},{"nct_id":"NCT06642272","title":"A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":17200,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT05239572","title":"Scaling Up NCD Interventions in South East Asia","phase":"NA","overall_status":"COMPLETED","enrollment_count":16850,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT04937816","title":"This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations","phase":"","overall_status":"COMPLETED","enrollment_count":16746,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05782881","title":"High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program","phase":"NA","overall_status":"UNKNOWN","enrollment_count":16000,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT02843399","title":"Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":15498,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05926414","title":"To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT03826290","title":"Evaluation of a Dashboard for Diabetes Care Integrated With the Electronic Health Record","phase":"NA","overall_status":"COMPLETED","enrollment_count":13155,"lead_sponsor_name":"University of Utah","has_results":false},{"nct_id":"NCT03960814","title":"A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine","phase":"","overall_status":"COMPLETED","enrollment_count":12847,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false}],"total":50},"guidelines":[{"drug_id":"semaglutide","guideline_body":"FDA label","recommendation":"as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus","line_of_therapy":"adj","evidence_grade":"not specified","guideline_year":null},{"drug_id":"semaglutide","guideline_body":"FDA label","recommendation":"to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events","line_of_therapy":"adj","evidence_grade":"not specified","guideline_year":null},{"drug_id":"metformin","guideline_body":"FDA label","recommendation":"ZITUVIMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.","line_of_therapy":"adj","evidence_grade":"not specified","guideline_year":null},{"drug_id":"empagliflozin","guideline_body":"FDA label","recommendation":"Empagliflozin, as a component of SYNJARDY or SYNJARDY XR, is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.","line_of_therapy":"adj","evidence_grade":"A","guideline_year":null},{"drug_id":"empagliflozin","guideline_body":"FDA label","recommendation":"Empagliflozin, as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of CV death and hospitalization for heart failure in adults with heart failure.","line_of_therapy":"adj","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}